The risk of PC in patients with FAMMM is estimated to be 13–22 times higher than in the general population and additionally increases to 38-fold in FAAMM subjects with CDKN2A mutations [100,101]. The gene discussed is CDKN2A; the disease is pachyonychia congenita.